Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

gar control," said John Amatruda, M.D., vice president, clinical research, Merck & Co., Inc. "This study examines the clinical effect of initial combination therapy with JANUVIA and metformin, the two drugs comprising JANUMET, over one year."

An important predictive factor of the magnitude of A1C reduction in response to anti-hyperglycemic therapy is a patient's starting level of A1C. In a subgroup analysis of patients grouped by severity of starting baseline A1C, treatment with JANUVIA 50 mg/metformin 1000 mg twice daily demonstrated increasing mean A1C reductions from baseline the higher the baseline A1C. A mean reduction of 3.1 percent was seen in patients with baseline A1C of 10 percent or more (n=17), while reductions of 2.2 percent, 1.7 percent, and 1.0 percent were seen with baseline A1C values of nine to 10 percent, eight to nine percent, and less than eight percent, respectively.

Investigational study showed JANUVIA significantly improved blood sugar control when added to sulfonylurea or to sulfonylurea and metformin vs. sulfonylurea or sulfonylurea and metformin alone (Poster #535-P; Study #035)

In this study, which was designed to examine the efficacy and safety of JANUVIA in patients with type 2 diabetes whose blood glucose levels were inadequately controlled (A1C levels of 7.5 percent to 10.5 percent) on a sulfonylurea (glimepiride) alone or on a sulfonylurea (glimepiride) plus metformin, JANUVIA demonstrated a significant mean difference from placebo in A1C of 0.9 percent in patients on glimepiride and metformin and 0.6 percent in patients on glimepiride alone (p less than 0.001 for both comparisons to the addition of placebo).

After a titration/stabilization period on glimepiride (at least 4 mg/day) with or without metformin (at least 1500 mg/day) and a 2-week placebo run-in, 441 patients with a mean baseline A1C of 8.3 percent were randomized to the addition of JANUVIA 100 mg once-daily or placebo for 24 weeks. Of thes
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:4/21/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that 2015 first quarter ... 2015.  On that day, the Company will hold a ... Time to discuss the results, followed by a question ... Chairman, President and Chief Executive Officer of CryoLife, Inc. ...
(Date:4/21/2015)... Mary Kelly, Ph.D ., is helping members of the Medical Group Managers Associations (MGMA) deal ... http://photos.prnewswire.com/prnh/20150420/199849 ... ... ... pulling your hair out of your head or going bankrupt," said Kelly, a popular keynote ...
(Date:4/21/2015)...  Edico Genome today announced a collaboration with ... processors to accelerate next generation sequencing (NGS) data ... primary and secondary NGS analysis in real time, ... analysis in the cloud and holds benefits for ... such as analysis of population-scale genomic data. ...
Breaking Medicine Technology:CryoLife Announces Release Date and Teleconference Call Details for 2015 First Quarter Financial Results 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 3Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 4Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 5Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 2Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 3
... Inc.,("CeloNova"), leading and accelerating healthcare solutions through ... breakthrough,results from the ATLANTA study of the ... the 20th Annual International Symposium on,Endovascular Therapy ... Corrado Tamburino, MD, President of the ...
... Ortho Women,s Health,& Urology(TM), Division of ... for ORTHO EVRA(R),(norelgestromin/ethinyl estradiol transdermal system) to ... includes two new additional estimates of relative,risk ... of 1.1,(indicating no increase in risk) and ...
Cached Medicine Technology:CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2ORTHO EVRA(R) Prescribing Information Updated 2ORTHO EVRA(R) Prescribing Information Updated 3
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... TX (PRWEB) April 21, 2015 The ... announced today it is opening its first freestanding emergency ... in Chandler, Arizona and will be licensed under Dignity ... the Dignity Health and Adeptus Health joint venture. , ... Regional and Mercy Gilbert Medical Centers said the new ...
(Date:4/21/2015)... & New York, NY (PRWEB) April 21, 2015 ... global provider of advanced delivery technologies and development ... today announced the launch of ADVASEPT™ Lock, a ... and efficient delivery of injectable medications. Easily opened, ... a safe, convenient and functional container closure with ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post presenting ... auto insurance prices . , Commuting on ... should review their insurance options before deciding what plan ... forms. Some of the popular policies provide liability, collision ... rates and find the best prices in their area ...
(Date:4/21/2015)... April 21, 2015 This year, in ... Skin Types, Inc.® (FIRST) will publish a unique awareness ... will run throughout the month of May and carry ... to Someone." The positioning was chosen to encourage ... skin disorder and to help support our mission of ...
Breaking Medicine News(10 mins):Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) Inc. (NYSE: ... device research and development outsourcing company with ... announced it has reached an agreement,with Johnson ... of,Janssen Pharmaceutica, N.V. (J&JPRD) to expand its ...
... ST. LOUIS, Oct. 15 Young Innovations, Inc.,(Nasdaq: ... third quarter,earnings results with a live and on-demand web ... Central Time. A live audio broadcast of the,call will ... the live audio broadcast will also be available through ...
... Options,(CCO), a leader in the development of innovative online, ... agreement with,the American Association for the Study of Liver ... unique Conference Coverage of AASLD,s,Liver Meeting(R) 2008, which will ... 4, 2008., "Clinical Care Options has a proven ...
... DUBLIN, Ohio, Oct. 15 Foresight Corporation ... Debra Strickland has joined the,company,s Development division ... http://www.newscom.com/cgi-bin/prnh/20081015/CLW134 ), In this role, ... customers to,propose and design new technical solutions, ...
... 15 Darwin,Professional Underwriters, Inc. (the "Company") (NYSE: ... meeting of the Company,s stockholders held on October ... Plan of Merger,(the "Merger Agreement"), dated as of ... Company Holdings, Ltd ("Allied World") and Allied,World Merger ...
... a sentry guarding the castle walls, a molecular messenger inside ... that could allow the invasion of an insidious enemy: Cancer. ... in its tracks, preventing an error that could lead to ... suggests that to be able to prevent abnormal cell proliferation, ...
Cached Medicine News:Health News:WuXi PharmaTech Expands Collaboration for Fully Integrated Services 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2Health News:American Association for the Study of Liver Diseases Enters Into Agreement With Clinical Care Options as Its Authorized Online Conference Coverage Provider for the Liver Meeting(R) 2008 2Health News:Debra Strickland joins Foresight Corporation in time for HIPAA 5010 Mandate 2Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 2Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 3Health News:Stem-cell sentry sounds the alarm to maintain balance between cancer and aging, U-M researchers find 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: